

Maja Stojancevic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6120941/publications.pdf>

Version: 2024-02-01

26
papers

704
citations

759233

12
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

1046
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Bile Acids in Hydrogel Pharmaceutical Formulations on Dissolution Rate and Permeation of Clindamycin Hydrochloride. <i>Gels</i> , 2022, 8, 35.	4.5	4
2	Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 879170.	3.5	7
3	The Effect of Deoxycholic Acid on Chitosan-Enabled Matrices for Tissue Scaffolding and Injectable Nanogels. <i>Gels</i> , 2022, 8, 358.	4.5	8
4	PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bile acids. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 158, 105668.	4.0	15
5	Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study. <i>Cells</i> , 2021, 10, 2437.	4.1	8
6	Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, , 1.	1.6	1
7	DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 1-14.	1.6	13
8	Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. <i>Pharmacological Research</i> , 2019, 146, 104333.	7.1	27
9	In silico Discovery of Resveratrol Analogues as Potential Agents in Treatment of Metabolic Disorders. <i>Current Pharmaceutical Design</i> , 2019, 25, 3776-3783.	1.9	7
10	Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 269-280.	1.6	23
11	Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. <i>Frontiers in Pharmacology</i> , 2018, 9, 1283.	3.5	159
12	Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. <i>Frontiers in Pharmacology</i> , 2018, 9, 1382.	3.5	78
13	IN VIVO EFFECTS OF URSODEOXYCHOLIC ACID ON DOXORUBICIN-INDUCED OXIDATIVE INJURY OF HEPATOCYTE. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-9-11.	0.0	0
14	The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 881-890.	1.6	9
15	Ursodeoxycholic acid sensitizes human breast adenocarcinoma cells to doxorubicin-induced apoptosis. <i>Toxicology Letters</i> , 2017, 280, S317-S318.	0.8	0
16	The influence of bile salts on the distribution of simvastatin in the octanol/buffer system. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 661-667.	2.0	9
17	An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. <i>Pharmaceutical Development and Technology</i> , 2015, 20, 702-709.	2.4	56
18	Metabolic activity of gut microbiota and xenobiotics. <i>Zbornik Matice Srpske Za Prirodne Nauke</i> , 2015, , 47-55.	0.1	2

#	ARTICLE	IF	CITATIONS
19	Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. <i>Journal of Pharmaceutical Innovation</i> , 2014, 9, 150-157.	2.4	58
20	The contribution of gut microflora to paracetamol metabolism. <i>Archives of Biological Sciences</i> , 2014, 66, 75-78.	0.5	0
21	The Influence of Intestinal Tract and Probiotics on the Fate of Orally Administered Drugs. <i>Current Issues in Molecular Biology</i> , 2014, 16, 55-68.	2.4	47
22	Application of bile acids in drug formulation and delivery. <i>Frontiers in Life Science: Frontiers of Interdisciplinary Research in the Life Sciences</i> , 2013, 7, 112-122.	1.1	100
23	An Insight on Differences in Availability and Reimbursement of Orphan Medicines Among Serbia, Bulgaria and Sweden. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 3236-3241.	1.3	15
24	Differences in the use of medicines for peptic ulcer and gastro-esophageal reflux disease between Serbia, Croatia and Sweden. <i>BMC Pharmacology & Toxicology</i> , 2012, 13, .	2.4	0
25	Considerable differences in the utilisation of antidiabetics between Serbia and Scandinavian countries. <i>BMC Pharmacology & Toxicology</i> , 2012, 13, .	2.4	0
26	The Impact of Farnesoid X Receptor Activation on Intestinal Permeability in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 631-637.	1.7	56